Cerebral venous thrombosis (CVT) is caused by partial or complete occlusion of the major
cerebral venous sinuses or the smaller feeding cortical veins which predispose to the risk of …

Objectives Current guidelines do not recommend direct oral anticoagulants (DOACs) to treat
cerebral venous thrombosis (CVT) despite their benefits over standard therapy. We …

Background: High level evidence for direct oral anticoagulants (DOACs) in patients with
cerebral venous thrombosis is lacking. We performed a systematic review and meta-analysis …

We aimed to investigate the efficacy and safety of rivaroxaban for acute and long-term
management of cerebral venous sinus thrombosis (CVST). This study reviewed CVST …

Direct oral anticoagulants (DOACs) are currently the preferred oral anticoagulant treatment
for most of the patients with deep vein thrombosis of the lower extremities and/or pulmonary …

Vitamin K antagonists (VKAs) are the standard oral anti‐coagulant treatment for patients with
cerebral venous thrombosis (CVT). However, the direct oral anti‐coagulants (DOACs) …

Rivaroxaban, as a novel oral anticoagulant agent, emerged in thrombosis management.
This study aimed to compare the efficacy and safety of once-daily rivaroxaban versus dose …

Objective Management of cerebral venous thrombosis (CVT) involves minimizing expansion
of the thrombus and promoting the recanalization of the venous sinus. While current …

Abstract Background and Objective Cerebral venous thrombosis (CVT) is a rare disease,
and data regarding direct oral anticoagulant therapy are insufficient. Apixaban could have a …

Cerebral venous thrombosis is a rare cause of stroke in young mostly female adults which is
frequently overlooked due to its variable clinical and radiological presentation. This review …